Please assess the completion status of the following clinical trial:

Trial Title: Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with bacterial conjunctivitis in 1 or both eyes;~* Able to understand and sign an informed consent form. If subject is \<18 years of age, the informed consent must be understood and signed by the subject's legally authorized representative;~* Agrees to comply with the visit schedule and other requirements of the study;~* Other protocol-specified inclusion criteria may apply.~Exclusion Criteria:~* Signs and symptoms of bacterial conjunctivitis for longer than 4 days prior to Day 1;~* Presence of concomitant viral infection;~* Infants with ophthalmia neonatorum of gonococcal, Chlamydia, herpetic or chemical origin;~* Infants whose birth mothers had any sexually transmitted disease within 1 month prior to delivery;~* Infants undergoing treatment for retinopathy of prematurity;~* Contact lens wear during the course of the study;~* Only 1 sighted eye or vision in either eye not correctable to 0.6 logMAR units (20/80) or better;~* Use of medications, as specified in the protocol;~* Any systemic or ocular disease or disorder, complicating factors or structural abnormality that could negatively affect the conduct or outcome of the study;~* Known or suspected allergy or hypersensitivity to fluoroquinolones;~* Pregnant, lactating, or of childbearing potential and not using adequate birth control to prevent pregnancy;~* Other protocol-specified exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Moxifloxacin AF (Type: EXPERIMENTAL): Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%, 1 drop in each eye twice daily for 3 days
- Vehicle (Type: PLACEBO_COMPARATOR): Moxifloxacin AF vehicle, 1 drop in each eye twice daily for 3 days

Based on this trial design, predict the completion outcome and termination type (if applicable).